Considering that EGFRvIII and MUC1 peptides are promising candidates for cancer therapy, our results pave the way to test the ability of engineered bacteria and OMVs to elicit anti-EGFRvIII and anti-MUC1 specific immune responses. This evidence concerns the gene MUC1 and cancer.